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between March and April 2014 and retrieved from an extra boost of ONCOVIEW 
database. ONCOVIEW is a continuous syndicated study on cancer treatment in 
the hospital setting, based on the collection of patient questionnaires. Patients 
inclusion criteria were the presence of an mCRC diagnosis, 3rd or later actual 
therapy line and no participation in a phase II or III clinical study. Information col-
lected included patient demographic characteristics, mCRC characteristics (TNM 
Classification, Karnofsky performance status scale and mutation analyses) and 
treatments (actual and previous schedules, dosages and durations). Furthermore, 
an evaluation of the “Rechallenge” occurrence, in other words the use in 3rd or 
later line of treatment of drugs previously used, has been performed. Results: 
261 patients diaries have been collected: 218 out of 261 patients were in third 
line of treatment, while 43 patients were in 4th or later treatment line. The 
most administered schema among third line patients was Capecitabine alone 
(63 patients), while the most used schema in fourth line was a combination of 
Fluorouracil and Folinic Acid (7 patients). About 40% of molecules administered 
in 3rd line and 67% of molecules administered in 4th line were used in previ-
ous lines. ConClusions: Results from the present study underline the unmet 
medical need in 3rd or later line of treatment of mCRC patients and the need for 
additional evidence-based treatment options.
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BurdeN of drug Waste iN oNCology: oPtimizatioN of resourCe use
Castro A.P., Alves A.F., Piedade A., Clark L.G.O, Bueno C.C., Minowa E.
Evidências Credibilidade Científica, São Paulo, Brazil
objeCtives: Minimizing waste of the use of drugs allows optimization of available 
resources in a scarce environment. Grouping patients may be an alternative to 
reduce drug waste in oncology. The aim of this study is to evaluate the economic 
impact of streamlined form of dispensation and percentage of drug wastage of 
the total drug expenditure in supplementary health system. Methods: Patients 
receiving antineoplasic treatment for stomach, colon, rectosigmoid, rectum, lung 
and breast cancer were eligible and selected retrospectively from the private mar-
ket administrative claims database (Evidencias database). Name and any other 
personal identification were not available at the database. Prescription and date 
of administration were collected from 3 selected private institutions consider-
ing large to small size in terms of patients. Waste of drug was calculated and it 
was defined as unavoidable or inappropriate clearance of partially drug use. All 
analyses were performed according to regimen and disease. Saving costs were 
calculated assuming minimization of waste by optimizing fully drug among group 
patients. Costs were derived from Simpro table. Exchange rate used was 1.00USD 
= 2.20BRL. Results: Seventeen drugs were identified among reported chemo-
therapy regimens in which 11 were analyzed due to potential of saving costs. From 
these, only 6 drugs could be rationalized. The optimization of drug dispensing 
would lead to a year savings of US$ 83.587,88, US$ 17.592,22 and US$ 8.225,24 to 
a large, medium and small clinic, respectively. Calculated drug wastage repre-
sented from 2% to 8% of the total drug expenditure, regarding on the antineoplastic 
used. Five of the 11 drugs did not cause savings due to small number of patients 
receiving those treatments. ConClusions: Grouping patients for drug wastage 
minimization is an effective way to reduce costs. Furthermore, savings can be 
increased by gathering patients of different diseases.
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resourCes utilizatioN for the iNvestigatioN of PulmoNary Nodules 
iN a uNiversity hosPital CeNter iN QueBeC, CaNada
Gouault-Laliberté A.1, Bergeron C.2, Lachaine J.1
1University of Montreal, Montreal, QC, Canada, 2CHUM Hotel-Dieu, Montreall, QC, Canada
objeCtives: Lung cancer is the leading cause of death among cancer patients; 
therefore, the detection of a pulmonary nodule cannot be ignored. With the 
increasing prevalence of lung nodule detection, the investigation requires a large 
number of health care resources. The objective of this study was to measure the 
health care resources used for the investigation of pulmonary nodules. Methods: 
A retrospective medical chart review was conducted at the CHUM-Hotel-Dieu in 
Montreal, Canada. Eligible patients were selected consecutively using the elec-
tronic appointment book of the pulmonary clinic, from January 1st 2011 to May 
23rd 2012. Inclusion criteria were: 40 year-old and over, presenting a pulmonary 
nodule ranging from 0.8 to 3.0 cm with no prior history of cancer in the last 
5 years and no history of lung cancer. Patient’s demographics, nodule charac-
teristics, medical information and resources utilization were extracted for 
each eligible patient. Results: A total of 47 patients (23 women and 24 men, 
mean age = 64) were included in the analysis. The mean nodule size was 1.8 
cm. Thirteen patients (28%) had a benign nodule and 34 (72%) had a malignant 
nodule. The most frequent non-invasive procedures were Thorax CT-Scan, PET-
Scan and Chest X-ray performed at least once in respectively 96%, 85% and 77% 
of patients. The minimally invasive procedures (bronchoscopy and transthoracic 
needle biopsy) and the invasive procedures (thoracoscopy and thoracotomy) 
were mostly performed in patients who were eventually diagnosed with a lung 
cancer. On average, patients with a benign nodule underwent 0.77 minimally 
invasive or invasive procedures vs. 1.94 for patients with a malignant nodule 
(p= 0.028). ConClusions: A significant amount of health care resources are 
deployed for the investigation of pulmonary nodules. This study tends to demon-
strate that minimally invasive and invasive procedures are mostly deployed for 
the diagnosis of malignant nodules.
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the PreveNtioN of skeletal-related eveNts iN PatieNts With BoNe 
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outcomes following BRCA testing in women with ovarian cancer and their female 
first-degree relatives. Two strategies are being compared: no testing versus BRCA 
testing. Estimates of cancer incidence and mortality, uptake and impact of risk-
reducing surgery and costs of BRCA testing, cancer treatment and palliative care 
were based on literature review. Outcomes are expressed as quality-adjusted life 
years (QALYs). One-way sensitivity analyses are conducted for key model param-
eters. Results: We first evaluated the cost-effectiveness of gene testing in relatives 
of ovarian cancer patients with BRCA mutations. Results showed this was associ-
ated with an ICER below the UK cost-effectiveness threshold of £20,000 per QALY 
gained compared with no testing. Sensitivity analyses showed the results were 
robust. ConClusions: We demonstrate that gene testing in unaffected female 
first-degree relatives of women with ovarian cancer due to BRCA mutations is cost 
effective. The final results will consider the cost effectiveness of offering BRCA 
testing to all eligible ovarian cancer cases and their unaffected female first-degree 
relatives.
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BurdeN of reNal imPairmeNt: relative health Care resourCe use iN 
Prostate CaNCer PatieNts With BoNe metastases
Qian Y.1, Arellano J.1, Gatta F.2, Burke T.P.3, Holbrook T.3
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World, Bollington, UK
objeCtives: Existing evidence suggests that around 49% of patients with bone 
metastases from solid tumors show evidence of renal impairment (eGFR< 60ml/
min/1.73m2) following diagnosis of bone metastases with approximately 80% of 
them developing chronic kidney disease. The objective of this analysis is to assess 
the economic and clinical burden of renal impairment in prostate cancer patients 
with bone metastases. Methods: Patients with a diagnosis of prostate cancer and 
bone metastases from the Adelphi Real World Disease Specific Programme USA 
2012 were included in the analyses. Propensity Score Matching was used; patients 
with evidence of renal impairment were matched with those without on a 1:1 basis, 
controlling for: age, BMI, smoking status, employment status, and relevant comor-
bidities. Outcomes included number of hospitalizations and length of stay in the 
past 12 months prior to the point of data collection. A Wilcoxon sign-rank test 
was used to quantify the impact of renal impairment. Results: 109 patients per 
group were included in the analyses (total 218). The renal impairment group was 
estimated to have an increased risk of inpatient visits of 63% (p= 0.036) compared 
to the control group (0.78 vs 0.48 inpatient visits per patient per year). Additionally, 
the renal impairment group had a mean of 2.43 (p= 0.027) more inpatient days per 
year than the control group (5.00 vs 2.56 inpatient days per patient per year). It was 
also observed that the patients in the renal impairment group were less likely to 
have received chemotherapy (37% vs 47% received chemotherapy). ConClusions: 
Findings suggest an increase in health care utilization in the hospital setting in 
prostate cancer patients with bone metastases and renal impairment. In addition, 
compromised renal function in those patients may potentially have restricted the 
use of nephrotoxic chemotherapy agents.
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1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2University of Twente, Enschede,  
The Netherlands
objeCtives: To estimate the expected benefits from a pivotal randomised con-
trolled trial of predictive biomarkers for high dose alkylating chemotherapy (HDAC) 
in triple negative breast cancer (TNBC) and to inform decisions about the design 
and priority of further studies. Methods: A markov decision model compared 
treating 40- years old TNBC women with HDAC based on four predictive biomarker 
strategies: 1) BRCA1-like by MLPA testing; 2) BRCA1-like by aCGH testing, 3) strategy 
1 followed by XIST and 53BP1 testing; and 4) strategy 2 followed by XIST and 53BP1 
testing, versus treating all patients with standard chemotherapy. A Dutch societal 
perspective and a 20-year time horizon were used. Input data came from literature 
and expert opinions. We assessed four primary outcomes: the expected value of 
(partial) perfect information (EV(P) PI), the expected value of sample information 
(EVSI) and the expected net benefit of sampling (ENBS) for the ongoing pivotal 
TNM trial (NCT01057069) and/or potential future studies. Results: The population 
EVPI was € 663 million (M). The EVPPI suggests prioritizing further research towards 
effectiveness parameters, specifically prevalence and positive predictive value of 
the biomarkers; response rates in biomarker negative patients and TNBC unclas-
sified patients, which are estimated to collectively have a value of information of 
circa € 630M. The value of further research on transition probabilities is estimated 
at € 41M, followed by utilities at € 34M and costs at € 34M. Further information on 
transition probabilities could be gathered from the TNM trial and that of effec-
tiveness parameters and costs from accompanying studies to this trial, altogether 
estimated to have an ENBS of € 657 M. ConClusions: Further research on predic-
tive biomarkers for HDAC should focus on gathering transition probability data 
from the current TNM trial, and on accompanying studies to derive data on other 
effectiveness parameters and costs.
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real World data iN oNCology: third- aNd fourth-liNe treatmeNts 
admiNistered iN metastatiC ColoN-reCtal CaNCer (mCrC)
Heiman F., Ripellino C., Visentin E.
CSD Medical Research S.r.l., Milan, Italy
objeCtives: The objective of this study was to assess the oncologists’ real clini-
cal practice in the management of mCRC patients, with a focus on the 3rd, 4th 
and later lines of therapy in Italy. Methods: Data presented in this study were 
collected from medical records obtained by Italian oncologists on mCRC patients 
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CaNCer – Patient-reported outcomes & Patient Preference studies
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targeted literature revieW of mediCatioN eveNt moNitoriNg 
systems to evaluate adhereNCe iN oBservatioNal real-World 
studies
Hanson K.A., Payne K.A.
United BioSource Corporation, Dorval, QC, Canada
objeCtives: To identify and review methods employed to evaluate medication 
adherence in studies of oral antineoplastic agents, with particular interest in the 
opportunities and challenges associated with medication event monitoring systems 
(MEMS) implemented in observational studies. Methods: A targeted literature 
review was conducted to identify studies that have measured adherence with anti-
neoplastic agents. Our review included studies that were published between January 
1990 and May 2014. Key data abstracted from each study included patient charac-
teristics, study design and duration, cancer type, treatment, and adherence meth-
odology and results. Based on preliminary results, a second targeted review was 
conducted to evaluate the literature on the risk of the Hawthorne effect in obser-
vational studies utilizing MEMS in any therapeutic area. Results: We identified 69 
studies that evaluated adherence to oral chemotherapy; 6 studies were interven-
tional and excluded from further review. Of the remaining 63 studies, 28 (44%) were 
prospective, 25 (40%) were retrospective, and 10 (16%) were cross-sectional. A total 
of 15 studies used MEMS to evaluate medication adherence. Among observational 
studies that utilized MEMS and evaluated the Hawthorne effect (n= 3), mixed results 
were observed. In two studies, patients reported their behavior was affected by their 
awareness of being evaluated. This was demonstrated by a significant decrease in 
adherence between months 1-3 in one study but not measured in the second. The 
third study showed no change in adherence scores over time and concluded there 
was no Hawthorne effect. Potential ways to minimize the Hawthorne effect include: 
study duration > 3 months, blinding patients and physicians to results of MEMS 
downloads, and use of a patient-completed ‘debriefing form’ to assess behavior 
modifications. ConClusions: MEMS have been utilized in observational studies 
evaluating oral antineoplastic agents. The Hawthorne effect may be present with 
MEMS caps, but can be minimized and is not prohibitive to study conduct.
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a systematiC revieW of health state utility values for advaNCed 
ovariaN CaNCer
Al-Dakkak I.1, Borrill J.2, Murphy E.1, Posnett J.1, Zhang Y.1
1PAREXEL International, London, UK, 2AstraZeneca, Macclesfield, UK
objeCtives: Identifying appropriate utility values to inform cost-effectiveness 
analysis is a common problem. The aim of this study was to review health-state 
utility values (HSUVs) for patients with advanced ovarian cancer and make recom-
mendations about their use in the economic evaluation of a targeted maintenance 
therapy for platinum-sensitive recurrent (PSR) ovarian cancer. Methods: A sys-
tematic search of Embase®, MEDLINE®, and MEDLINE®in Process was conducted 
in June 2013 for studies reporting direct (standard gamble (SG) or time trade off 
(TTO)) or indirect (EQ-5D, SF-6D, or HUI-3) utility values for patients with advanced 
ovarian cancer. HTA agency websites were also searched. Study design, country, 
HSUV elicitation method, health state (HS) description, and who valued the HS were 
extracted. Mean (SD) utility scores, or medians (ranges), if means were unavailable, 
were recorded for each HS. Results: A total of 10 publications were found, rep-
resenting five primary sources of utility values. Two were derived from trial-based 
patient-reported EQ-5D profiles; one derived profiles from patients with ovarian 
cancer and utility values from a sample of the general population using a SG; two 
derived HSUVs from a sample of women without cancer using a TTO. These studies 
reported utilities for 18 different health states. Where comparisons were possible, 
utility values differed widely: clinical remission 0.83-0.977; progression-free after 
recurrence 0.50-0.715; progressive disease 0.40-0.725. None of the studies reported 
values for patients receiving maintenance therapy. ConClusions: There is limited 
health-state utility data for advanced ovarian cancer and wide variations in sam-
ple size, methods of elicitation, populations used to provide utility values, and in 
health state descriptions. Further research is required to provide robust estimates 
to populate an economic model for a targeted maintenance therapy for PSR ovarian 
cancer. Given the limitations of the current evidence base additional methods, such 
as mapping algorithms should be considered.
PCN179
health-state utility values iN Breast aNd Prostate CaNCer 
measured usiNg the eQ-5d: a systematiC revieW of the literature
Hughes R., Mitchell C.R., Bishop R.S., Fotheringham I
Oxford PharmaGenesis Ltd, Tubney, Oxford, UK
objeCtives: In cost–effectiveness analyses (CEA), a paucity of health-related qual-
ity of life (HRQoL) data often necessitates use of utility values from populations 
which may be ill-matched with the disease modelled. Use of the most pertinent data 
increases model precision and the accuracy of CEA. This systematic literature review 
aimed to identify utility values derived from the EQ-5D in patients with breast 
cancer (BC) or prostate cancer (PC). Methods: A systematic search was conducted 
using Medline, Embase and Cochrane databases. Eligible studies for inclusion com-
prised those reporting EQ-5D utility values in patients with BC or PC at any stage, 
undergoing or not receiving treatment. Results: 31 studies reported relevant data 
(BC, 17; PC, 14). Utility values for metastatic BC (6 studies) ranged from 0.55–0.75 
and were lower for patients receiving palliative chemotherapy (CT) or terminal care 
(0.51–60), while for stage 0–III disease (9 studies), values ranged from 0.74–0.88. In 
early-stage BC there was little change during follow-up; for stage II/III BC, rapid 
and sustained recovery was observed following high-dose (HD) CT and was main-
tained long-term post-HDCT and following adjuvant CT. Values for metastatic PC (9 
studies) ranged from 0.63–0.85 and were lower for patients with bone metastases, 
worse performance status or undergoing palliative care. For localised PC (2 studies), 
objeCtives: Skeletal-related events (SREs) defined as pathologic fracture, radiation 
to bone, surgery to bone and spinal cord compression, are common consequences 
of bone metastasis. Prior studies have shown that SREs increase the utilization of 
health care resources, including hospitalizations. We estimated the decrease in hos-
pitalizations when a novel superior therapy is used (denosumab), in substitution 
of zoledronic acid (zol), to treat patients with bone metastases secondary to breast 
cancer in Germany. Methods: An analysis was run for predicting the number of SREs 
avoided and the reduction in number of hospitalizations attributable to treatment 
with denosumab. The number of breast cancer patients was collected from a German 
registry using the International Classification of Disease codes. Epidemiological data 
were then utilized to derive the number of hospitalizations due to bone metasta-
ses. The number of patients treated for SREs prevention was obtained from market 
research and applied to either treatment. The total number of SREs observed was 
based in the SREs rates seen in a phase 3 clinical trial. German data from a multina-
tional retrospective chart review was used to quantify the inpatient hospitalization 
rates and length of stay associated with each type of SRE. Results: Approximately 
9,500 patients per year with breast cancer and bone metastases were estimated to 
be treated with denosumab or zol in Germany. The resulting 2,100 SREs prevented 
per year led to a reduction of approximately 700 hospitalizations per year. The total 
number of days per inpatient stay avoided by using denosumab instead of zol was 
approximately 5,000 per year. ConClusions: The superior efficacy of denosumab 
compared to zol reduces the disease burden by decreasing the number of SREs and 
consequently the number of hospitalizations and inpatient days.
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CliNiCal imPlemeNtatioN of geNomiC seQueNCiNg iN PediatriC 
oNCology: ideNtifiCatioN aNd valuatioN of resourCes aNd Costs 
assoCiated With Next-geNeratioN seQueNCiNg
Oberg J.A., Sireci A.N., Mansukhani M.M., Nagy P.L., Glade Bender J.L, Kung A.L.
Columbia University, New York, NY, USA
objeCtives: Beyond understanding the pure cost of genomic sequencing, the 
real costs associated with implementing next-generation sequencing (NGS) into 
clinical practice are currently unknown. To elucidate the real costs and to pro-
vide a potential benchmark for reimbursement, a pilot study was conducted to 
identify and valuate the resources related to conducting clinical cancer whole-
exome (cWES), transcriptome, and targeted panel sequencing in a cohort of 
pediatric cancer patients. Methods: A cost model was calculated using 25 pedi-
atric cancer patients who underwent clinical genomic sequencing at Columbia 
University Medical Center. Our institutional workflow developed by the Precision 
in Pediatric Sequencing (PIPseq) Program in the Division of Pediatric Oncology and 
the Personalized Genomics Medicine Laboratory in the Department of Pathology 
guided the identification of resources and costs associated with NGS. Results: 
17 pediatric patients received cWES testing and 11 patients received transcrip-
tome testing using Illumina HiSeq 2500 technology. 7 patients received targeted 
cancer panel testing using Illumina MiSeq technology. The total cost per case per 
test [cWES (tumor/normal), $4,459; transcriptome (tumor), $1,764; targeted panel 
(tumor), $383) was calculated from summing the total variable cost (reagent cost, 
pathologist time) with the fixed cost per case (annual machine cost, annual main-
tenance, tech labor cost, informatics cost, space for NGS hardware, server time, 
NGS analysis lease, and data storage). Clinical utility was demonstrated by iden-
tifying a potentially actionable mutation in 24% of participants. ConClusions: 
Since the reimbursement landscape for clinical genomic sequencing is currently 
unknown, a comprehensive cost calculation reflecting resource utilization across 
the whole sequencing workflow including costs associated with directed therapy 
based on molecular profiling results is necessary. These data serve as a starting 
point toward identifying and valuating resources associated with NGS and serve 
as a first step toward demystifying reimbursement for clinical genomic sequenc-
ing in Pediatric Oncology.
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amNog BeNefit assessmeNt for oNCologiC aNd orPhaN drugs iN 
germaNy – imPliCatioNs for PriCe disCouNts
Theidel U., Wahlers K., Mittendorf T.
Herescon GmbH, Hannover, Germany
objeCtives: With the start of AMNOG in 2011, industry is demanded to submit 
and defend evidence as well as negotiate discounts for new drugs with an addi-
tional patient benefit in Germany. The National Association of Statutory Health 
Insurances (SpiBu) negotiates with a discount on the ex-factory price on top of 
a mandatory discount. Evaluating final prices, questions arise regarding factors 
might influence discounts and impact the German market especially for oncologic 
and orphan drugs. Methods: A database containing detailed information for 
all past assessments was used to explore potential impact factors for discounts. 
Starting with an analysis of background information (discount, areas etc.) descrip-
tive statistics were employed. Furthermore, we analyzed past assessments with 
respect to: number and size of target population, results of the benefit assessment, 
change in ex-factory price, magnitude of discount, incorporation of quality of life 
evidence, and acceptance of comparator therapy among others. Results: Until 
June 2014 24 price negotiations were completed for oncologic and/or orphan drugs 
(neoplasm: 16, orphan drugs [w/o oncologics]: 8). It is inconclusive, if the scale of 
benefit influences the price discount. An additional benefit was granted by the 
G-BA in 21 of 24 cases. The magnitude of the discount tends to be higher in groups 
with smaller target populations and quality of life evidence has no influence on 
the negotiated discount. Discount rates might be smaller if the companies do 
not deviate from recommendations given by the G-BA. In addition to discounts, 
some companies needed to lower their ex-factory price. ConClusions: Whereas 
binding and strict rules are in place for the benefit assessment itself, there is 
no algorithm for prediction of levels of price discounts. To decrease uncertainty 
for scenario planning a set algorithm or procedure would be preferable. Further 
research is needed to evaluate those criteria.
